ValueAct Capital Supports Immucor Transaction

SAN FRANCISCO, July 5, 2011 /PRNewswire/ -- ValueAct Capital, the largest outside shareholder of Immucor, Inc. ("Immucor"), announced today that it supports the agreement to sell the company for $27 per share in an all cash transaction to TPG Capital.

"ValueAct Capital is pleased with today's announcement and believes that the transaction is an excellent outcome for all Immucor's shareholders," stated G. Mason Morfit, a member of the Board of Directors at Immucor and a Partner and Management Committee Member at ValueAct Capital. "We strongly support this transaction, believe it to be in the best interests of all shareholders, and intend to tender our shares of Immucor."

About ValueAct Capital

ValueAct Capital®, with more than $6.5 billion in investments and offices in San Francisco and Boston, seeks to make active strategic-block value investments in a limited number of companies.  The Principals have demonstrated expertise in sourcing investments in companies they believe to be fundamentally undervalued, and then working with management and the company's board to implement strategies that generate superior returns on invested capital. ValueAct Capital concentrates primarily on acquiring significant ownership stakes in publicly traded companies through both open-market purchases and negotiated transactions.

SOURCE ValueAct Capital